Myelodysplastic Syndrome
Conference Coverage
For leukemias, COVID-19 death risks tied to poor prognoses, ICU deferrals
COVID-19 death risks for acute leukemias were driven by poor physician-assessed prognoses and opting out of recommended ICU care.
Conference Coverage
Genotype, need for transfusion predict death in VEXAS syndrome
Among patients with a methionine-to-valine substitution in the UBA1 gene, survival was significantly worse, compared with patients with two other...
Feature
VEXAS: A novel rheumatologic, hematologic syndrome that’s making waves
Conference Coverage
Omidubicel improves on umbilical cord blood transplants
Conference Coverage
Using engineered T cells reduced acute, chronic GVHD
Conference Coverage
Chronic GVHD therapies offer hope for treating refractory disease
From the Journals
Extended virus shedding after COVID-19 in some patients with cancer
Some patients, including stem cell transplant and CAR T recipients, may require extended periods of isolation.
Conference Coverage
In MDS, transplant ups survival in elderly and may be reimbursed
Conference Coverage
Prevention of HMA failure a goal for high-risk MDS posttransplant
Conference Coverage
Are HMAS appropriate for posttransplant maintenance in acute leukemias?
Not yet, hematologist/oncologist tells colleagues at ALF meeting.
Conference Coverage
HMAs plus novel agents may improve outcomes in higher-risk MDS